Hematopoietic SCT (HSCT) is one treatment modality for hematological malignancies. It is increasingly common but remains centralized in certain hospitals wherein procedures and protocols can vary. This study examined 100-day readmission for patients with hematological malignancies undergoing HSCT in Taiwan from the years 2001 to 2006. Of particular interest was an examination of how HSCT program characteristics might influence outcomes. This population-based retrospective cohort study with longitudinal follow-up used Taiwan's National Health Insurance Research Database. A generalized linear model with a logistic-dependent variable representing being admitted or not admitted was used to model 100-day readmission, adjusting for the nested design. There were 718 HSCT recipients for hematological malignancies in the 5-year study period from 10 HSCT programs. In spite of the average length of stay of 43.71 days (s.d. ¼ 25.75) days, 52% of recipients were readmitted within 100 days of discharge. Ownership status, the number of HSCT hematologists, and the ratio of HSCT procedures to HSCT hematologists independently predicted 100-day readmission after adjusting for clustered data and controlling for recipient characteristics.
Introduction
As one treatment modality for malignant and nonmalignant diseases, more patients with hematologic cancers are undergoing hematopoietic SCT (HSCT) worldwide. 1 Patients remain immunocompromised within 1 year after HSCT because of conditioning regimens, hematopoietic stem cells, and immunosuppressants. Therefore, patients are often readmitted to hospitals after HSCT for treatment of complications, such as infections, GVHDs, and so on. Unscheduled readmission is one indicator of quality of patient care that should be monitored. Moreover, readmission is highly correlated with increased costs and mortality within 100 days after HSCT discharge from hospitals. 2, 3 Many models examine outcomes and most include patient, process, and organizational characteristics. 4, 5 According to these models, structural characteristics of HSCT programs and hospitals may influence readmissions of HSCT patients. Only two studies reported the descriptive results of hospital readmissions after HSCT. 6, 7 Hospital readmission rates within 6 months were 51% and 20% within 3 1 2 years after HSCT discharge. 6, 7 Both descriptive studies represented single-hospital experiences from the United States and Spain.
No population-based studies have examined 100-day readmissions among adult HSCT patients. Similarly, there are few studies examining factors influencing 100-day readmissions among HSCT recipients. We hypothesized that hospital ownership and program characteristics such as the volume of HSCT procedures and the number of hematologists might affect 100-day readmission. Hence, the aim of this retrospective study is to describe the rate, reasons, timing, and the number of 100-day readmissions and to determine the influence of HSCT program characteristics on hospital readmission within 100 days of discharge among all adult patients undergoing HSCT in Taiwan for selected hematological cancers.
Patients and methods
The study design was a population-based retrospective cohort with longitudinal follow-up design using Taiwan's National Health Insurance Research Database (NHIRD) between 2001 and 2006. The database represents claims and administrative support files for the National Health Insurance program in Taiwan. 8 The NHIRD is created by the Bureau of National Health Insurance and the National Health Research Institute in order to effectively and quickly reply to present and emerging health issues.
All patients who underwent an HSCT procedure from 2001 to 2005 were identified using ICD-9-CM procedure codes representing HSCTs (4100-4109) from the principal and four secondary procedure codes in the hospital discharge data. To achieve a more homogenous sample, eligibility was limited to HSCT patient's age X18 years with hematological malignancies rather than hematological diseases that may be treated with HSCT. Those who were admitted for infusion of stem cells, donor lymphocytes, and managing post-transplant complications, as well as those admitted for the second HSCT, were excluded. Only patients from the 10 hospitals with cumulative HSCT volume 410 were included.
All measured variables were extracted and validated from the in-patient expenditures by admissions, registry for catastrophic illness patients, and registry for contracted medical facilities. These study variables, including the organizational and program characteristics, and the recipient characteristics, are listed in Table 1 and used for both descriptive and as primary predictors of patient outcomes.
Data analysis
All analyses were conducted with SPSS 17.0 (IBM Corporation, Somers, NY, USA) and SAS 9.2 (SAS Institute Inc., Cary, NC, USA). Bivariate analyses of factors associated with 100-day readmission were performed using the SAS PROC GENMOD program (SAS Institute Inc.), adjusting for the nested design. Predictor variables with P-values p0.20 were retained for the multivariate models. 9 Exchangeable and independent correlation structures were used to compare the results of generalized estimating equation after adjusting for nested design because the unstructured correlation structure did not work for these data. This might be due to the small size of clusters, resulting in poor estimation of the correlation coefficients. 9 The best model was selected using modelbased s.e. estimates. The final model of exchangeable or independent correlation structures was chosen by inspecting smallest values of quasi-information criteria and quasilikelihood under independence criterion (QICu).
Data quality
The limitations of the in-patient claims data in this study with variations of miscoding HSCT procedures and comorbidity and coding errors of stem cell resource were consistent with other studies. 10 Iezzoni indicated that abstracted hospital data comprised of errors and used them with caution. 10 Careful assessment of data quality by Structural characteristics of programs and hospitals S-I Hsieh et al validating coding using other codes (for example, V428, V4281, V4282, and 99685) and with a Taiwan hematologist was undertaken to make the best use of the data as possible. 
Results

Program and organizational characteristics
Recipient characteristics
The total number of HSCT recipients was 718 from 2001 to 2005 across the 10 study hospitals. Table 3 summarizes descriptive characteristics of HSCT recipients. Age at time of transplant ranged from 18 to 66 years with a mean of 36.81 (s.d. ¼ 11.42). The majority of recipients were male (58.5%). The proportion of HSCT recipients with lymphoma and multiple myeloma progressively increased, although HSCT recipients with CML decreased as illustrated in Figure 1 . Most of HSCT recipients (92.9%) were categorized as having one of the five primary diseases. One-tenth of HSCT recipients had at least one comorbidity, including hypertension, liver disease, and diabetes mellitus. The median of days from diagnosis to HSCT was 245 days for the entire sample. Two-thirds of recipients (67.7%) underwent HSCT within 1 year after diagnosis. Recipients with a second HSCT comprised 5.6% of the sample. More than half of the HSCT procedures (57.2%) were autologous HSCT across the 5 years. Characteristics of 100-day readmissions HSCT recipients who died during the HSCT admission (N ¼ 62) were excluded from the study of 100-day readmission. As summarized in Table 4 , more than half (52%) of HSCT recipients experienced a hospital readmission within 100 days of discharge. The most common reasons for 100-day readmission were immunological (for example, infections). The proportion of complications may add to 4100% because recipients may have more than one reason for 100-day readmission. The majority of HSCT recipient rehospitalizations occurred within 30 days of discharge. Some recipients (21.2%) had multiple readmissions within 100 days after discharge. One recipient had 13 readmissions within 100 days after discharge.
Clustered binomial logistic regression to predict 100-day readmission The multivariate analysis shows that ownership status, the number of HSCT hematologists, and the ratio of HSCT procedures to HSCT hematologists are independent predictors on 100-day readmission after adjusting for clustered data and controlling for three recipient characteristics. HSCT recipients in public hospitals are 77% more likely to have 100-day readmission (OR ¼ 1.77; 95% CI ¼ 1.27, 2.46) as compared with those in private not-for-profit hospitals after adjusting for clustered data and controlling for other variables. As the number of HSCT hematologists increases by one, the likelihood of having 100-day readmission increases by 7% (OR ¼ 1.07; 95% CI ¼ 1.01, 1.12). As the ratio of HSCT procedures to HSCT hematologists increases by one unit, the likelihood of having 100-day readmission decreases by 13% (OR ¼ 0.87; 95% CI ¼ 0.82, 0.93).
The covariates of disease nature, comorbidity, and transplant type are statistically significant independent predictors of 100-day readmission after discharge. The risk of 100-day readmission is 3.5 times higher (OR ¼ 3.50; 95% CI ¼ 2.16, 5.66) for HSCT recipients with transformed or mixed diseases than for those with primary diseases. In HSCT recipients with any comorbidity recorded during HSCT hospitalization and all other variables are held constant, the likelihood of having 100-day readmission increases by 2.23 times (OR ¼ 2.23; 95% CI ¼ 1.11, 4.47). If HSCT recipients are transplanted with allogeneic HSCT and all other variables are held constant, the likelihood of having 100 day readmission increases by 71% (OR ¼ 1.71; 95% CI ¼ 1.21, 2.42). A stratified analysis was also done to examine the confounding effect of disease nature on 100-day readmission. Predictors were not identical between the mixed or transformed disease group and the primary diseases. However, the sample sizes of mixed or transformed diseases are small (N ¼ 46), which prevented model convergence. 
Discussion
This is the first study to characterize HSCT for hematological malignancies in Taiwan. Although most published studies report outcomes in only one hospital/program, this study utilized population-based claims data to measure the HSCT patients' outcome. Moreover, this study focused on the impact of program characteristics on 100-day readmission outcome.
Factors affecting 100-day readmission
Findings of more readmissions with allogeneic HSCT recipients and the most common reason for readmission with infection are consistent with Grant et al. and Moya et al. 6, 7 However, this study has a higher proportion of 100-day readmission (52%) than Moya et al. 7 (20% within 3 years 4 months) and Grant et al. 6 (51% at least one time within half year). Yet, it is also possible that studies in the United States, Spain, and Taiwan had different expected payers and control mechanisms of readmission, and that Taiwan's recipients had longer length of stay than Grant et al. 6, 7 A surprising result is that private not-for-profit hospitals and the ratio of HSCT procedures to HSCT hematologists are significantly favorable predictors (for example, less likely to have 100-day readmission). Similarly, the number of HSCT hematologists is a significantly unfavorable predictor (for example, more likely to have 100-day readmission). There are several possible explanations for private not-for-profit hospitals being less likely to have 100-day readmission. First, private not-for-profit hospitals might have more frequent follow-up schedules for early assessment and management of complications. Second, private not-for-profit hospitals might have their own mechanisms to control for readmission. Readmission within 30 days after an initial discharge is considered as an undesired outcome that should be avoided by the healthcare provider. 11, 12 Despite no difference in comorbidity between public hospitals and private nonprofit hospitals (w 2 (1) ¼ 0.07, P ¼ 0.80), recipients in public hospitals are more likely to have 100-day readmission than those in private nonprofit hospitals. The finding is inconsistent with a study of readmission in patients with acute myocardial infarction at not-for-profit hospitals wherein 1-, 2-, and 3-month readmission after initial discharge was higher than in for-profit hospitals. 11 The investigator concluded that readmission is influenced by patients' clinical conditions rather than hospital quality.
A possible explanation for recipients in programs with more HSCT hematologists being more likely to have 100-day readmission is measurement error. This measure only counted the number of HSCT hematologists in the index HSCT data without taking into consideration how the HSCT hematologists are assigned to patient care. For example, if the HSCT hospital has four HSCT hematologists, two HSCT hematologists work as a team to see HSCT hospitalized patients during 1 month and shift to another team monthly. Also, the median number of HSCT hematologists (3.6) seems slightly lower as compared with the United States (median ¼ 4). 13 Recipient characteristics were also found to have an impact on 100-day readmission. Having mixed or transformed disease puts HSCT patients at higher risk for more post-HSCT complications, such as infection and relapse. [14] [15] [16] [17] [18] Comorbidity is likely to influence readmission by increasing the risk of regimen-related toxicity that can compromise recipients' performance status post-HSCT. 19 Similarly, allogeneic HSCT recipients had more readmissions because they usually need to take immunosuppressive drugs within þ 100 days to prevent or control GVHD. Overall, their immunity is lower than autologous HSCT recipients. These findings are consistent with those of Grant et al. 6 that allogeneic HSCT recipients and recipients with higher comorbidities were more frequently readmitted within a half year after discharge than those with autologous HSCT or fewer comorbidities.
Strengths and limitations
This study has several strengths. First, the data represented a population-based claims relational database that included all adult HSCT recipients in Taiwan. Second, this study Table 5 Bivariate and multivariate analyses for 100-day readmission using the exchangeable structure of SAS PROC GENMOD program after adjusting for nesting design (N ¼ 656) adopted a broad framework that included recipient and program/organizational characteristics to examine the effectiveness of HSCT. Third, using the mixed or transformed diseases vs primary disease variables was a creative approach to examine the effect of recipient characteristics on 100-day readmission and overall survival using limited clinical variables. Fourth, as part of this study data quality of the NHIRD has been extensively examined and documented, supporting the feasibility of using these data for longitudinal, population-based studies. Fifth, although this study had small cluster sizes, data were analyzed by adjusting for correlated data in order to reduce underestimated s.e. and incorrect inferential estimates. Despite these strengths, several limitations are acknowledged, primarily related to the data source. It was necessary to rely on ICD-9-CM codes to define the sample, the diseases, disease nature, comorbidity, transplant type, the number of HSCT procedures, and reasons for readmission. As in the United States, the ICD-9-CM diagnostic and procedure codes in the NHIRD do not have a specific date of occurrence. Therefore, a comorbidity that a patient was admitted with was difficult to differentiate from complications. Moreover, specific ICD-9-CM codes for some important clinical variables were not included, such as differentiating myeloablative or non-myeloablative HSCT, donor information (for identifying related or unrelated HSCT), graft failure, GVHD, and other case mix variables for conducting risk adjustment. This study relied on ICD-9-CM procedure codes to identify the sample. Every effort has been made to reduce the threats to internal validity of this study, including extensively examining all records in the three relational databases, confirming coding decisions with mentors and HSCT hematologists, and correcting and documenting errors for data quality.
Similarly, although this study used population-based data and identified adult hematological malignancies, the sample size was still small compared with developed countries. However, HSCT is a treatment modality for the minority of the population with hematological cancers. It must also be acknowledged that 100-day readmission would be disparate between allogeneic and autologous HSCT. Unfortunately, the number of HSCT recipients precluded the ability to conduct separate analyses for the allogeneic and autologous recipients. Yet, the research has adjusted for types of HSCT in the multivariate analysis.
A final limitation is related to external validity. This study can only reflect Taiwan's HSCT experience. As there are variations in recipient, program/organizational, and contextual characteristics across countries, it is likely that these findings are not completely generalizable. On the other hand, the findings were compared with other studies from Spain, Switzerland, and the United States in the discussion and consistent findings were noted in the effect of HSCT structural characteristics on 100-day readmission. 6, 7, 11, 13 Implications For practice, this study provides needed benchmarks to compare Taiwan's HSCT outcomes to other HSCT programs across countries. More than half of HSCT recipients were readmitted within 100 days and a large proportion of HSCT recipients were readmitted within 30 days and had at least one readmission. The most common cause of 100-day readmission is immunological complications, such as bacterial, viral or fungal infections. Clinicians need to consider how to decrease preventable readmission despite a long length of stay. The HSCT case manager is the best person to engage in educational programs, 24-h telephone, e-mail, Skype or MSN (messenger) counseling. All of these may decrease the need for readmission. Furthermore, this study may encourage clinicians to perform further evidence-based interventional studies in order to review and evaluate the discharge process as well as discover effective strategies for reducing infection problems among HSCT recipients during homecare.
For health-care policy, an area in which health policymakers may intervene is related to data sources that support assessment of quality and cost analyses. Although the NHIRD data have been used to conduct diverse studies, such as the one reported here, data quality needs to be improved. Although hospital providers know the importance of documenting patients' symptoms and signs, assessment, and treatment plans on the medical charts, documentation still has inconsistencies. Despite efforts of Taiwan Medical Record Management Association that have improved accurate coding of ICD-9-CM, issues related to data quality of the NHIRD remain. 20 Audits of ICD-9-CM coding and administrative information of the Bureau of National Health Insurance have been conducted, but a systematic approach is needed. In order to capture outcome variations between recipients and across hospitals, Taiwan may also consider developing a registry that supports HSCT around the country. Similar multi-center, prospective data collection efforts include specific clinical data, recipient characteristics, and program/organizational factors and make it possible to assess the effectiveness and efficiency of HSCT programs. Japan, Australia, Turkey, France, England, and the United States have a national registry for HSCT.
For research, this study is one of the first to use this national database to examine recipient and program/ organizational characteristics for their effects on patient outcomes. Hopefully, this study will encourage other researchers to conduct population-based health outcome studies using statistical procedures that properly account for nested data. Although length of stay and medical fees were not examined in this study, the NHIRD has these variables and understanding how length of stay and charges vary across hospitals would be useful. Knowing predictors of both outcomes and both variations across hospitals may help researchers to compare Taiwan's unique HSCT experience with other HSCT programs in other countries in order to improve the quality of care.
In conclusion, this population-based study of HSCT procedures for patients with hematological malignancies found that program characteristics influenced 100-day readmission. This might be expected as the hospital organizational and 'system' characteristics can be altered to influence readmission. Although a registry would be ideal, this study also demonstrated the feasibility of using claims data to study an entire population of patients undergoing HSCT.
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